SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--TIME Magazine has selected Fluidigm’s JunoTM system as one of the top 25 inventions of 2015. In its annual round-up of the best inventions that make the world better, smarter and more fun, TIME magazine was particularly impressed with Juno’s ability to simultaneously amplify DNA from many biological samples, in just hours.
Leading scientists around the world are already using the Juno platform for research on crop genetics and livestock management to improve world food supplies, and on marine life and fisheries to sustain aquatic populations. Looking forward, there is great potential for the Juno technology to advance genetic testing and help enable the future of precision medicine.
“We thank TIME Magazine’s editors for recognizing Juno as one of their Best Inventions of 2015. We at Fluidigm are passionate about enabling breakthroughs that can change the understanding and application of biology, and in turn positively impact life around the globe. Our customers' work is so important that we strive to bring creative solutions to market with a remarkable user experience. It is incredibly rewarding to have our efforts recognized in this way by TIME,” said Gajus Worthington, Fluidigm Chief Executive Officer and President.
Use of Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to the potential for the Juno technology to advance genetic testing and help enable the future of precision medicine. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including challenges inherent in developing, manufacturing, launching, marketing, and selling new products. Information on these and additional risks affecting Fluidigm’s business and operating results are contained in its filings with the Securities and Exchange Commission, including its most recently filed Quarterly Report on Form 10-Q for the quarter ended September 30, 2015. These forward-looking statements speak only as of the date hereof and Fluidigm disclaims any obligation to update these statements except as may be required by law.
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for growth markets such as single-cell biology and production genomics. We sell to leading academic institutions, clinical laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multi-parameter mass cytometry technology, and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs, while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@Fluidigm), Facebook page (https://www.facebook.com/Fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo and Juno are trademarks or registered trademarks of Fluidigm Corporation.